Clinical trial
Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With…
NCT00168012 · CSL Behring, Industry · Completed
Key facts
| NCT number | NCT00168012 |
|---|---|
| Title | Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID) |
| Official title | An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 in Patients With Primary Immunodeficiency Diseases (PID) |
| Lead sponsor | CSL Behring, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency |
| Intervention type | Drug |
| Interventions | Immunoglobulins Intravenous (Human) |
| Enrollment | 42 |
| Start date | Sep 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Feb 11, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: